Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692619 | 0.92 | ELANE (0.39) | ALDH1A1CES2CES1ELANEKDM4E | |
| SCHEMBL712791 | 0.87 | MAOB (0.35) | SMN1; SMN2ALDH1A1CES2MAOBELANE | |
| SCHEMBL717323 | 0.83 | ELANE (0.36) | ALDH1A1MAOBELANEKDM4ECYP2C19 | |
| SCHEMBL10396191 | 0.79 | NPSR1 (0.37) | SMN1; SMN2ALDH1A1CES2CES1ELANE | |
| SCHEMBL772101 | 0.77 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL771097 | 0.77 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL10899304 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HSD17B10 | |
| SCHEMBL772723 | 0.74 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL24908565 | 0.73 | ESR1 (0.40) | SMN1; SMN2ALDH1A1ARKDM4EHPGD | |
| SCHEMBL7084775 | 0.73 | RORC (0.38) | SMN1; SMN2MAPTXBP1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2657304-B1 | AZO DYE, OCULAR LENS MATERIAL, METHOD FOR PRODUCING OCULAR LENS MATERIAL, AND OCULAR LENS | MENICON CO LTD (JP) | 2022-12-07 | — | — | EP | disclosed |
| US-9017716-B2 | Ophthalmic lens | MENICON CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| EP-2657304-A1 | AZO DYE, OCULAR LENS MATERIAL, METHOD FOR PRODUCING OCULAR LENS MATERIAL, AND OCULAR LENS | Menicon Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2180366-B1 | SILICONE-CONTAINING OCULAR LENS MATERIAL WITH HIGH SAFETY AND PREPARING METHOD THEREOF | MENICON CO LTD (JP) | 2013-09-25 | — | — | EP | disclosed |
| US-20130202551-A1 | IONIC COMPOUND, COMPOSITION, CURED MATERIAL, HYDROGEL AND OPHTHALMIC LENS | MENICON CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-2581394-A1 | IONIC COMPOUND, COMPOSITION, CURED PRODUCT, HYDROGEL, AND OCULAR LENS | Menicon Co., Ltd. (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-2514791-A1 | ANTHRAQUINONE PIGMENT, OCULAR LENS MATERIAL USING SAME, OCULAR LENS MATERIAL MANUFACTURING METHOD, AND OCULAR LENS | Menicon Co., Ltd. (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120148519-A1 | OPHTHALMIC LENS | MENICON CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| EP-2453293-A1 | OPHTHALMIC LENS | Menicon Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-8124668-B2 | Silicone-containing ocular lens material with high safety and preparing method thereof | MENICON CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-2180366-A1 | Silicone-containing ocular lens material with high safety and preparing method thereof | MENICON CO., LTD. (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-20060142410-A1 | Silicone-containing ocular lens material with high safety and preparing method thereof | MENICON CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| US-7037954-B2 | Ocular lens material | MENICON CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1582910-A1 | HIGHLY SAFE SILICONE-CONTAINING MATERIAL FOR OCULAR LENS AND PROCESS FOR PRODUCING THE SAME | MENICON CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| EP-1197782-B1 | MATERIAL FOR OCULAR LENS | MENICON CO LTD (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-20040039077-A1 | Ocular lens material | MENICON CO., LTD. | 2004-02-26 | — | — | US | disclosed |
| US-6638991-B2 | Lens material comprising a copolymer derived from a polysiloxane endcapped with acrylated urethane groups, a silicon-containing alkyl methacrylate, a hydrophilic monomer, and a crosslinking monomer; oxygen permeability, strength | MENICON CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| US-20020198280-A1 | Material for ocular lens | MENICON CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| EP-1197782-A1 | MATERIAL FOR OCULAR LENS | MENICON CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148519-A1 | OPHTHALMIC LENS | AQP4, CRYAA, UACA | SMN1; SMN2 4810/4885ALDH1A1 2666/4885CES2 3168/4885 |
| US-20130202551-A1 | IONIC COMPOUND, COMPOSITION, CURED MATERIAL, HYDROGEL AND OPHTHALMIC LENS | CRYZ, CRYAA, VIL1 | SMN1; SMN2 3739/4885ALDH1A1 2196/4885CES2 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.